The title of the NOX presentation at ASCO is:
A phase 1 study of NOX66 in combination with carboplatin in patients with end stage cancer
Graham Kelly appears to think that the use of NOX66 plus chemotherapy has considerable commercial potential, but what would he know?
We should find out just why he remains confident when the updated abstract is published on the Noxopharm website on its day of presentation.
The title of the NOX presentation at ASCO is: A phase 1 study of...
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $29.22M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 52445 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 14492 | 2 |
View Market Depth
| Last trade - 10.49am 27/11/2024 (20 minute delay) ? |
| NOX (ASX) Chart |
Day chart unavailable
